#HSCT
44-year-old man with AML after HSCT, on glucocorticoids: right otalgia after a right facial rash; ulcers in the right oral cavity.

Otoscopy: blisters with vascular ectasia around the right eardrum (A); left ear normal (B).

Diagnosis?

#ENT #Transplant #IDSky #MedSky
1/2
November 16, 2026 at 6:57 AM
Hsct
November 10, 2026 at 3:40 AM
Donor-derived CD19-CAR T cells show enhanced expansion and persistence, achieving complete responses at low doses post-HSCT relapse. TSCM cells outperform standard CAR T cells. PMID:42066750, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1 #Medsky #Pharmsky #RNA #ASHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1
No description available
www.cell.com
November 12, 2026 at 4:00 PM
Donor-derived CD19-CAR T cells from TSCM showed 3x better expansion and persistence than standard CAR T cells, achieving complete responses at low doses post-HSCT. PMID:42066750, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1
No description available
www.cell.com
November 9, 2026 at 11:00 PM
🔥 iMeta latest article: Hepatic sinusoidal obstruction syndrome and the search for a modifiable endothelial state onlinelibrary.wiley.com/doi/10.1002/...
Hepatic sinusoidal obstruction syndrome and the search for a modifiable endothelial state
Pyrrolizidine alkaloid (PA) exposure, haematopoietic stem cell transplantation (HSCT), and repeated oxaliplatin treatment provide distinct contexts for sinusoidal endothelial injury, with differing m...
onlinelibrary.wiley.com
November 11, 2026 at 12:25 PM
🆕 New Phase 3 findings from JCO:

Adding sitagliptin to standard ATG-based prophylaxis cut the cumulative incidence of grade II–IV acute GVHD by over half (14.7% vs. 31.6%) in alternative-donor #HSCT, without compromising transplant efficacy.

Full Article🔽:
https://bit.ly/4k3hKu6
November 10, 2026 at 11:10 PM
Are routine chest X-rays still necessary for neutropenic fever in auto-HSCT? 🩻

We caught up with Kristina Helms, CNP, APRN, MSN, of the @mayocliniccancer.bsky.social, at #JADPROLive to break down new findings on its clinical utility for oncology patients.

Full Video!
📹 https://bit.ly/4zPbriA
November 10, 2026 at 10:53 PM
Syndrome-oriented CNS infectious complications after HSCT and CAR T-cell therapy, part 1 - viral encephalitis, meningitis, and myelitis: recommendations from the Practice Harmonization & Guidelines Committee of the EBMT.
José Luis Piñana, et al.
eClinicalMedicine 2026
doi.org/10.1016/j.ec...
Redirecting
doi.org
November 8, 2026 at 5:27 PM
In patients with newly diagnosed #MMsm not undergoing upfront autologous HSCT, indefinite maintenance therapy with lenalidomide was not found to produce significantly longer OS when compared with fixed-duration therapy, at 68.6% vs. 69%, respectively: https://ow.ly/fNjQ5104i3I
November 6, 2026 at 2:30 PM
Celaid Therapeutics Raises JPY 400 million in Series B Financing to Advance Ex Vivo Hematopoietic Stem Cell (HSC) Expansion - bioinformant.com/celaid-thera...
Celaid Therapeutics Raises JPY 400 million in Series B Financing to Advance Ex Vivo Hematopoietic Stem Cell (HSC) Expansion | BioInformant
For decades, hematopoietic stem cell transplantation (HSCT) has been one of the most successful cell therapies in medicine, with more than 40,000 transplants performed worldwide each year. Yet the fie...
bioinformant.com
November 7, 2026 at 2:07 AM
Donor-derived CD19-CAR TSCM cells show enhanced expansion & persistence vs. standard CAR T cells, achieving complete responses at low doses post-HSCT relapse. PMID:42066750, Cell 2026, @Cell https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://www.cell.com/cell/fulltext/S0092-8674(26)00383-1
No description available
www.cell.com
November 4, 2026 at 6:00 PM
you saw in the case of HSCT in ALD that they begin to SELECT THE FITTEST ie youngest patients and then compare their stem cell transplant results with the others, who were already the ones who were deemed in most cases to have a disease 'too far advanced'. They have no random control groups, nothing
with THIS level of rigor you can of course not force people to follow your therapies, it is nonsense. You have to persuade people with RIGOR. RIgor is the only way that people with conflicting data or opinions can be persuaded. if you don't have rigor you don't have anything. No science, nothing.
medical people have essentially empirical BELIEF SYSTEMS, it is essentially a single catastrophe, no differential equations, actually no real math at all except first semester statistics. And not even that they understand and APPLY properly.- But elementary logic is the worst, if logic breaks down..
November 4, 2026 at 2:38 PM
🔗 #StemCellEvidence link to:
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
by Guillerault et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia
Myeloablative conditioning before hematopoietic stem cell transplantation (HSCT) during childhood or adolescence reduces adult uterine volume, but its impact on future pregnancies remains uncertain. T...
www.stemcellevidence.com
November 3, 2026 at 2:07 PM
🔗 #StemCellEvidence link to:
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
by Moser et al.
www.stemcellevidence.com/alerts/artic...
#MedSky
Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome
This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European cen...
www.stemcellevidence.com
November 3, 2026 at 4:51 PM
Long term F/U of 80 systemic sclerosis pts Rx w/ autologous HSCT. W/ Med. 9.2 yrs F/U progression-free survival = 81%, 72% @5 yrs, & 60% @10 yrs. 18 pts died; death due to HSCT in 6%, SSc progression in 11%, CA in 2 (3%), serious infx 2 (3%), 34 (43%) maintained remission - no DMARDs buff.ly/ZFy3MkO
Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study
This study provides long-term follow-up data after autologous HSCT in patients with systemic sclerosis allowing robust assessment of response rate, late complications, and sustained treatment…
buff.ly
November 2, 2026 at 4:03 PM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 8:24 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 8:24 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 5:39 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 5:33 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 5:39 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 5:33 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 2:34 AM
Global Transplant Medical Lead, HSCT - Morristown, NJ Job educativ.net/jobs/job/67708...
October 31, 2026 at 2:34 AM